H1 2026 results reinforce Telix’s shift to profitable growth
In its H1 2026 interim results presentation delivered to investors on 20 August 2026, Telix Pharmaceuticals reported group revenue up 22% year-on-year to US$477M, alongside a swing to net profit of US$38M from a loss of US$2M in H1 2025.
Management outlined Adjusted EBITDA growth of 148% YoY to US$52M, with the company tracking toward the upper end of FY 2026 revenue guidance of US$950M–US$970M. The update framed a clear strategic message: a profitable, cash-generative commercial base is now funding an expanding late-stage pipeline. Precision Medicine drove the result, while Telix Manufacturing Solutions (TMS) remains in a deliberate investment phase.
When big ASX news breaks, our subscribers know first
H1 2026 financial results at a glance
Telix delivered broad-based improvement across growth, profitability and cash generation. The following table summarises the headline metrics reported for the period.
| Metric | H1 2026 | H1 2025 | YoY Change | Comment |
|---|---|---|---|---|
| Revenue | $477M | $390M | +22% | Driven by Precision Medicine demand |
| Adjusted EBITDA | $52M | $21M | +148% | Operating leverage improving |
| Net profit | $38M | –$2M | +$41M | Swing to profitability |
| Gross margin | 55% | 53% | +2pts | Pricing and manufacturing efficiencies |
| R&D | $124M | $82M | +51% | Reinvestment into late-stage pipeline |
| Cash balance | $252M | $142M (31 Dec 2025) | +78% | Strengthened balance sheet |
One item warrants clarification. The income statement recorded US$40M in “Other income”, representing a non-refundable upfront payment from Regeneron. This is a one-off contribution rather than recurring product revenue, and is excluded from FY 2026 revenue guidance.
What is radiopharmaceutical precision medicine?
Two terms recur throughout the results. PSMA (prostate-specific membrane antigen) is a protein found on prostate cancer cells that acts as a target for both imaging and therapy. TAM refers to total addressable market, or the estimated number of eligible patients or scans.
Precision Medicine powers the result
The Precision Medicine segment was the engine of the period. Revenue rose 27% YoY to US$388M, gross margin expanded to 65%, and segment Adjusted EBITDA increased 26% YoY to US$132M, driven by continued adoption of Illuccix and Gozellix across all markets.
Quarter-on-quarter momentum was evident. Precision Medicine global sales rose from US$186M in Q1 2026 to US$202M in Q2 2026, representing growth of 31% YoY and 9% QoQ. Illuccix now holds marketing authorisations in 24 countries and is commercially available in 22, including 17 across Europe.
Key global footprint milestones reported during the half included:
- China Phase 3 study completed, with the New Drug Application (NDA) under review
- Japan Phase 3 patient enrolment completed
The Illuccix China regulatory pathway has progressed through NMPA acceptance on the back of Phase 3 data showing 94.8% detection accuracy and treatment decision changes in 67.2% of cases, with the Grand Pharma partnership de-risking the commercialisation approach into a market of 134,000-plus annual prostate cancer diagnoses.
Management attributed the segment’s performance to differentiated products, a disciplined reimbursement strategy and ongoing global expansion, noting favourable product mix and pricing discipline supported margin gains.
A late-stage pipeline moving toward the clinic and market
The profits generated by Precision Medicine are funding a broad pipeline, with R&D running at 26% of revenue. Two near-term imaging catalysts stand out.
Pixclara (floretyrosine F 18) carries a PDUFA date of 11 September 2026 and is described by the company as potentially first to market (U.S.) for imaging of gliomas. Separately, the Pixlumi Marketing Authorization Application (MAA) has been accepted for review in Europe. Zircaix is progressing a Biologics License Application (BLA) resubmission and holds both Breakthrough Therapy Designation and Fast Track Designation.
Telix is advancing five late-stage clinical programs:
- TLX591-Tx (ProstACT Global) — FDA alignment on safety data to progress to Part 2, in mCRPC
- TLX101-Tx (IPAX BrIGHT) — first cohort enrolment completed, in recurrent glioblastoma
- TLX250-Tx (LUTEON) — dosing started, in advanced ccRCC
- TLX090-Tx (SOLACE) — dosing patients, for bone pain
- BiPASS — nearing completion of enrolment
The company also highlighted its co-development and co-commercialization agreement with Regeneron, focused on next-generation alpha therapies including lung cancer targets. The US$40M upfront payment from that agreement has already been received.
The BiPASS opportunity: doubling the market
The BiPASS study underpins the long-term volume story behind the imaging franchise. The thesis is to move PSMA-PET imaging to the pre-biopsy stage, potentially expanding the U.S. total addressable market by an incremental 800,000+ scans per year, roughly doubling the addressable market and aiming to change the standard of care.
A further indication expansion adds to the opportunity. The Pixclara brain-metastasis indication is estimated to expand the addressable market by an incremental 100,000+ scans per year. Both initiatives remain subject to ongoing study progress and regulatory outcomes.
FY 2026 guidance and the road ahead
Management reaffirmed FY 2026 revenue guidance of US$950M–US$970M, with revenue expected to come in at the upper end of that range, underpinned by around 25% growth in Precision Medicine revenue. This guidance excludes the US$40M non-refundable Regeneron payment.
R&D guidance was set at US$230M–US$270M, which the company framed as a deliberate reinvestment strategy rather than a cost blowout, supporting pipeline expansion including TLX597-Tx, the Regeneron collaboration and Pixclara indication expansion. Manufacturing capacity is also scaling, with the Sacramento/RLS network, Seneffe GMP build-out in Belgium, Yokohama ARTMS QIS installation in Japan and a new North Melbourne facility positioned to de-risk future therapeutic launches.
Key 2026 catalysts highlighted in the presentation included:
- Pixclara PDUFA decision (11 September 2026)
- Zircaix BLA resubmission
- TLX591-Tx ProstACT Global Part 1 data readout
- Illuccix China regulatory approval and launch
- TMS North Melbourne site opening
- Target of 50 ARTMS QIS installations globally
The update reinforced a consistent investment thesis. A profitable, cash-generative commercial base, supported by a US$252M cash balance, is funding a broad and catalyst-rich pipeline heading into the second half of FY 2026.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ investors who stay ahead of the market the moment announcements land. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts today.